Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer
- 663 Downloads
Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.
Key wordsOsteonectin promoter construction Suicide gene therapy Prostate cancer Adenoviral vector HSV-tk enzymatic assay
This work was financially supported in part by the Ministry of Science and Technology in Taiwan (Grant No. 106-2320-B-038-055, 106-2320-B-038-056 and 107-2113-M-038-057), and the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE).
- 3.Sung SY, Chang JL, Chen KC, Yeh SD, Liu YR, Su YH, Hsueh CY, Chung LW, Hsieh CL (2016) Co-targeting prostate cancer epithelium and bone stroma by human osteonectin-promoter-mediated suicide gene therapy effectively inhibits androgen-independent prostate cancer growth. PLoS One 11(4):e0153350CrossRefGoogle Scholar